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Adenomyosis
Wei Zheng and Boya Deng
Abstract
Adenomyosis is a benign uterus disease in which the invasion of the endometrial 
glands and/or stroma within myometrium is found and usually appears between the 
ages of 40 and 50 years in women. There are several differences in their pathogen-
esis. The secondary dysmenorrhea and menorrhagia are the common symptoms. 
Ultrasound sonography, MRI, CA125, and histological examination can be helpful 
for the diagnosis of adenomyosis. The treatment of adenomyosis depends on the 
patient’s age, symptoms, and desire for future fertility, including medical treatment 
and surgical treatment.
Keywords: adenomyosis, hyperestrogenism, progesterone, laparoscopic, GnRHa, 
LNG-IUS
1. Introduction
Adenomyosis is a benign uterus disease in which the invasion of the endometrial 
glands and/or stroma within myometrium is found and usually appears between the 
ages of 40 and 50 years in women [1]. It can result in debilitating pelvic pain, abnor-
mal uterine bleeding, and infertility. It was first described in 1860 by Rokitansky, 
and in 1896, Cullen suggested the term “adenomyosis.” Adenomyosis is an estrogen-
dependent disease similar to endometriosis and it regresses rapidly after the meno-
pause. However, adenomyosis is a poorly understood gynecologic disease.
2. Prevalence
Most cases of adenomyosis were discovered in multiparous women during the 
transitional years (40–50 years). Women of age range 30–60 years also can be 
affected. The incidence of adenomyosis remains unknown, because the disease 
is usually recorded on the base of hospital and surgical reports, it is generally 
estimated that 20% of women have adenomyosis. However, an analysis of multiple 
myometrial sections may reveal an incidence as high as 65% [2].
3. Pathogenesis
Endometriosis and adenomyosis are closely linked diseases, but there are several 
differences in their pathogenesis. Four theories have been proposed to explain 
adenomyosis: heredity, trauma, hyperketonemia, and viral transmission. Although 
the exact cause is unknown, the most widely accepted theory of histogenesis was 
proposed by Meyer in 1900. Meyer postulated that the normal barrier between 
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Figure 1. 
The thickening of the uterine well is made up of trabeculated areas, stippled or granular in appearance, with 
small yellow or darker cystic tissues which contain serous fluid or stale blood.
the endometrium and myometrium is somehow attenuated. The most held theory 
regarding adenomyosis is the endometrial basalis layer invades through the end 
myometrial junctional zone (JZ) into the myometrium after trauma on the endo-
metrium [3]. Estrogen and progesterone likely play a role in its development after 
invagination of the endometrium. Another theory is that adenomyosis is caused by 
metaplasia of the Müllerian tissue [4]. Ren et al. demonstrated that Belin 1 expres-
sion was decreased in eutopic endometrium, and negatively correlated with serum 
CA125 and pelvic pain. Belin 1, therefore, may play a role in the pathogenesis and 
progression of adenomyosis [5]. The tissue injury and repair (TIAR) mechanism 
is activated in response to tissue auto-traumatization. This mechanism leads to a 
specific physiological process that promoted local production of Bcl-2, and plays an 
important role in the occurrence and development of adenomyosis [6]. The levels 
of anti-smooth muscle antibody positive and collage I positive myofibroblasts are 
significantly higher in the JZ of women with adenomyosis than in those without [3], 
as the evidence of tissue microtrauma and activation of the TIAR mechanism.
Hyperestrogenism is suggested to result from increased local aromatization, and 
decreased local estrogen metabolism in the eutopic and ectopic endometrium of 
patients with adenomyosis. Hyperestrogenism may promote elevated mechanical 
strains and stresses that could injure cells in the junctional zone (JZ) [7, 8].
Recently, studies of embryonic pluripotent Müllerian remnants and differentia-
tion of adult stem cells have also been reported [4, 9, 10]. Epithelial-mesenchymal 
transition (EMT) is biological process involved in embryological development, 
tissue repair, and cancer cell migration, but the mechanism triggering EMT in 
adenomyosis has not yet been elucidated [11].
4. Pathology
There are two types of adenomyosis: focal and diffuse. The typical uterus with 
adenomyosis is enlarged compared to normal ones. The thickening of the uterine 
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wall was made up of focal or diffused adenomyosis areas stippled or granular in 
appearance, with darker cystic lesions that may contain serous fluid or stale hemor-
rhage (Figure 1); in some rare cases, adenomyosis may present as a large chocolate 
cyst (cystic adenomyosis) [12].
The microscopic feature of adenomyosis is the presence of endometrial tissue 
including glands and stroma cells within the myometrium (Figure 2).
More than 80% of women with adenomyosis have some pathological process in 
the uterus. Patients have associated leiomyomas [13] and endometriosis [14].
5. Symptoms
Early adenomyosis is asymptomatic, only about one-third of women with adeno-
myosis have symptoms. Secondary dysmenorrhea and menorrhagia are the common 
symptoms. The severity of dysmenorrhea correlates with the increasing number of 
invasions. It is thought to be caused by increased prostaglandin production found in 
adenomyosis tissues compared with normal myometrium. Approximately 60% of 
women suffer from abnormal uterine bleeding; menorrhagia and dysmenorrhea are 
the two major adenomyosis-associated symptoms, and 30% of patients with these 
symptoms have typical secondary, progressive dysmenorrhea [15]. Menorrhagia 
with adenomyosis includes excessively heavy or prolonged menstrual bleeding. 
Some patients’ symptoms are not common but may include menstrual irregularities. 
Some patients with adenomyosis have the history of infertility or abortion.
6. Diagnosis
6.1 Ultrasound sonography
Imaging with transvaginal ultrasound (TVUS) can identify the subtle myo-
metrial changes of adenomyosis, the findings may include: (1) the anterior or 
posterior myometrial wall appearing thicker, (2) small myometrial hypoechoic 
cysts, (3) endometrium JZ extending into the myometrium, (4) appearance of 
Figure 2. 
The presence of endometrial tissue, glands and stroma are within the myometrium.
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focal adenomyosis as discrete hypoechoic nodules that may be differentiated from 
leiomyoma by poorly defined margins, and (5) myometrial hyperplasia. Three-
dimensional transvaginal ultrasonography can improve the diagnostic accuracy 
with variable ranges of sensitivity between 70 and 93% and specificity between 86 
and 93% for diagnosing adenomyosis by TVUS [16].
6.2 MRI
MRI has been shown to be highly accurate in the diagnosis of adenomyosis.
It can differentiate between adenomyosis and the fibroids. MR imaging may be 
complimentary (Figure 3). The main MRI criterion for diagnosing adenomyosis 
is by detection of high-intensity tiny myometrial cysts in the inner myometrium, 
irregularity, and asymmetric junctional zone. MRI can distinguish the subtypes of 
adenomyosis: diffuse and solid or cystic adenomyoma.
6.3 CA-125
There are studies find the levels of the ovarian epithelial tumor antigen CA-125 
patients with adenomyosis might be high. After the therapy, it might decrease.
6.4 Histological examination
The gold standard for the diagnosis of adenomyosis is histological examination. 
The diagnosis is usually based on histologic findings in surgical specimens after 
hysterectomy.
Figure 3. 
MRI of adenomyosis.
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7. Treatment
The treatment of adenomyosis depends on the patient’s age, symptoms, and 
desire for fertility.
7.1 Medical treatment
7.1.1 GnRHa
Gonadotropin-releasing hormone (GnRH) agonists have been shown to release 
pain and reduce the adenomyotic lesions’ size [17].
GnRHa agonists cause hypoestrogenism, resulting in adverse effects such as hot 
flashes, vaginal dryness, and bone mineral loss.
7.1.2 Oral dienogest
Dienogest, a novel 19-nortestosterone derivative, is a synthetic oral progestin 
that is highly selective for progesterone receptors. Dienogest reduces the painful 
symptoms in women with endometriosis [18].
A recent study of the oral dienogest for premenopausal menorrhagia and pelvic 
pains in women with uterine adenomyosis indicated that oral dienogest might be 
a valuable alternative for treatment of premenopausal pelvic pains in women with 
uterine adenomyosis [19]. Another pilot study presented the results on the efficacy 
and safety of dienogest in the treatment of symptomatic adenomyosis. Dienogest 
significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 
and CA 19-9 levels [20].
7.1.3 LNG-IUS
Menorrhagia associated with adenomyosis can be treated with levonorgestrel-
releasing IUS that releases levonorgestrel, 20 μg/day. It is placed in uterus within 
7 days of menstruation.
7.1.4 Other drugs
Danazol has been the medical therapy for treatment of adenomyosis for several 
years. Danazol has a direct antiestrogen effect on endometriotic lesions
Nonsteroidal anti-inflammatory drugs (NSAIDs) can relieve mild pain associ-
ated with adenomyosis. NSAIDs are the analgesia and anti-inflammatory agents 
through the pathway of inhibition of PGE2 and COX-2.
Combination oral contraceptives can be used to induce endometrial atrophy 
and decrease endometrial prostaglandin production to improve dysmenorrhea and 
menorrhagia.
7.2 Surgical treatment
7.2.1 Hysterectomy
This is the definitive treatment of adenomyosis; however, most of the patients 
do not accept the surgery of total hysterectomy, with or without ovarian conserva-
tion. Patients who have a desire for pregnancy can be treated by focal adenomyosis 
resection using either laparotomy or laparoscopic surgery.
Endometriosis
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7.2.2 Ablation of adenomyosis using high-intensity focused ultrasound (HIFU)
High-intensity focused ultrasound (HIFU) ablation, which was initially 
developed for the treatment of solid tumors, is now successfully implemented 
in the treatment of uterine fibroids and adenomyosis [21–23]. Several pro-
spective studies have demonstrated ranges of effectivity between 81 and 
87% [21–24]. After HIFU therapy, MRI showed the diffuse adenomyosis in 
Figure 4(a) and the nonperfused area of the lesion without damage to the sur-
rounding normal tissue in Figure 4(b). Rarely serious complications including 
major permanent injuries were observed. Ultrasound-guided HIFU ablation 
may be a safe and effective noninvasive alternative in the treatment of symp-
tomatic adenomyosis.
7.2.3 Ablation of endometrium with adenomyosis using MEA or NovaSure
Endometrial ablation or resection using hysteroscopy has been used to success-
fully treat dysmenorrhea and menorrhagia caused by adenomyosis. But it is not 
acceptable if future pregnancy desired.
7.2.4 Uterine artery embolization (UAE)
It has been used to relieve symptoms for adenomyosis. UAE has favorable 
outcomes in symptomatic adenomyosis, both short-term and long-term [25]. Due to 
the limited clinical data, the side effects on ovarian function and future pregnancy 
after UAE are still not clear.
Figure 4. 
MRI of adenomyosis in (a) showed the diffuse lesion before HIFU, and (b) showed the nonperfused area of the 
lesion without damage to the surrounding normal tissue after HIFU.
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8. Adenomyosis malignant transformation
As with other pathologies of endometriosis, adenomyosis may goes malignant 
transformation. It is not clear whether some malignancies being as such or progress 
from benign disease to malignant. The neoplasia arises coincidentally in continuity 
with endometriotic implants.
Although adenomyosis is usually benign, it might also be a precursor of malig-
nant disease. As the incidence of adenomyosis malignant transformation is low, and 
its clinical manifestation is nonspecific, it may only be confirmed by postoperative 
pathological examination. Malignant neoplasia occurs rarely in the glands and/
or stroma; these tumors may be in the form of adenocarcinomas, sarcomas, or 
carcinosarcomas. Further investigations with large samples may provide additional 
data of the prognosis of adenomyosis malignant transformation [26]. Some of the 
risk factors of malignant adenomyosis include age between 40 and 50 years, early 
menarche, short menstrual cycle, first delivery at young age, fertility, curettage 
during early trimester of pregnancy, obesity, and history of tamoxifen intake. The 
expression of both PR and ER was positive in patients with endometrial carcinoma 
combined with adenomyosis or endometrial carcinoma combined with uterine 
fibroids, and the expression of p53 and Ki67 was positive in eutopic malignant 
endometrium and negative in normal ectopic endometrium, which may provide 
additional pathological data on adenomyosis malignant transformation [26, 27].
9. Conclusion
Adenomyosis is a condition in which the inner lining of the uterus (the endome-
trial) breaks through the uterus myometrium. Adenomyosis can cause menstrual 
cramps, lower abdominal pain, and heavy periods, and negatively impact on a 
woman’s quality of life. The condition can be located throughout the entire endome-
trium or localized in one spot. Nonsteroidal anti-inflammatory drugs (NSAIDs) can 
relieve mild pain associated with adenomyosis. Symptoms such as heavy or painful 
periods can be controlled with hormonal therapies. HIFU focused on a small focal 
region to increase tissue temperature sufficiently, which causes irreparable cell 
damage in the target adenomyosis lesions at a certain depth. And uterine artery 
embolization, the minimally invasive procedure, used to block the blood vessels 
therefore causes adenomyosis shrinks. Endometrial ablation destroys the lining of 
the uterus and relief from the heavy bleeding. The only definitive cure for adeno-
myosis is a hysterectomy.
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